Diagnosis & Differentiation
Deep learning with deep convolutional neural network using FDG-PET/CT for malignant pleural mesothelioma diagnosis
Oncotarget 2021 June 18 [Link] Kazuhiro Kitajima, Hidetoshi Matsuo, Atsushi Kono, Kozo Kuribayashi, Takashi Kijima, Masaki Hashimoto, Seiki Hasegawa, Takamichi Murakami, Koichiro Yamakado Abstract Objectives: This study analyzed an artificial intelligence (AI) deep learning method with a three-dimensional deep convolutional neural network (3D DCNN) in regard to diagnostic accuracy to differentiate malignant pleural mesothelioma (MPM)…
Read MoreCLDN15 is a novel diagnostic marker for malignant pleural mesothelioma
Scientific Reports 2021. June 15 [Link] Masayuki Watanabe, Tomohito Higashi, Kana Ozeki, Atsuko Y Higashi, Kotaro Sugimoto, Hayato Mine, Hironori Takagi, Yuki Ozaki, Satoshi Muto, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Yutaka Shio, Hiroyuki Suzuki, Hideki Chiba Abstract Malignant mesothelioma is a cancer with a poor survival rate. It is difficult to diagnose mesotheliomas because…
Read MoreOxytocin receptor is a promising therapeutic target of malignant mesothelioma
Cancer Science 2021 June 11 [Link] Yuta Kodama, Ichidai Tanaka, Tatsuhiro Sato, Kazumi Hori, Soei Gen, Masahiro Morise, Daisuke Matsubara, Mitsuo Sato, Yoshitaka Sekido, Naozumi Hashimoto Abstract Malignant mesothelioma (MM) is one of the most aggressive tumors. We conducted bioinformatics analysis using Cancer Cell Line Encyclopedia (CCLE) datasets to identify new molecular markers in MM.…
Read MoreImmune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma
Drugs 2021 June [Link] Wanyuan Cui, Sanjay Popat Abstract Immune checkpoint inhibitors (ICI) have shown important but variable efficacy in mesothelioma despite a lack of strong biological rationale. Initial trials assessed ICI monotherapy in patients with relapsed mesothelioma, with objective response rates (ORR) between 4.5 and 29%, median progression-free survival (PFS) between 2.5-6.2 months, and…
Read MorePathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma
Cancers 2021 May 24 [Link] Francesca Napoli, Angela Listì, Vanessa Zambelli, Gianluca Witel, Paolo Bironzo, Mauro Papotti, Marco Volante, Giorgio Scagliotti, Luisella Righi Abstract Malignant pleural mesothelioma (MPM) is a rare and highly aggressive disease that arises from pleural mesothelial cells, characterized by a median survival of approximately 13-15 months after diagnosis. The primary cause…
Read MoreNIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
Journal of Translational Medicine 2021 May 31 [Link] Vilde Drageset Haakensen, Anna K Nowak, Espen Basmo Ellingsen, Saima Jamil Farooqi, Maria Moksnes Bjaanæs, Henrik Horndalsveen, Tine Mcculloch, Oscar Grundberg, Susana M Cedres, Åslaug Helland Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour. For patients with inoperable disease, few treatment options are…
Read MoreUpdate on Diagnosing and Reporting Malignant Pleural Mesothelioma
Acta Medica Academica 2021 April [Link] Ivana Savic, Jeffrey Myers Abstract In this review, we summarize current approaches to diagnosis of malignant pleural mesothelioma, focusing on the distinction from benign mesothelial proliferations and other malignant tumors. Current recommendations for reporting histological sub-type and tumor grade are also reviewed. Particular emphasis is placed on immunohistochemical and…
Read MoreOld Borders and New Horizons in Multimodality Imaging of Malignant Pleural Mesothelioma
The Thoracic and Cardiovascular Surgeon 2021 June 1 [Link] Katharina Martini, Thomas Frauenfelder Abstract Background: The purpose of this article is to describe the various imaging techniques involved in detection, staging, and preoperative planning in malignant pleural mesothelioma (MPM) focusing on new imaging modalities. Methods: For this purpose, first a brief summary of the etiology…
Read MoreDevelopment of unenhanced CT-based imaging signature for BAP1 mutation status prediction in malignant pleural mesothelioma: Consideration of 2D and 3D segmentation
Lung Cancer 2021 July [Link] Xiao-Jie Xie, Si-Yun Liu, Jian-You Chen, Yi Zhao, Jie Jiang, Li Wu, Xing-Wen Zhang, Yi Wu, Hui Duan, Bing He, Heng Luo, Dan Han Abstract Objectives: We aimed to explore the feasibility of 2D and 3D radiomics signature based on the unenhanced computed tomography (CT) images to predict BRCA1-associated protein…
Read MoreThe value of cytology in distinguishing malignant mesothelioma: An institutional experience of 210 cases reclassified according to the International System for Reporting Serous Fluid Cytopathology (ISRSFC)
Cytopathology 2021 May 28 [Link] Patrizia Straccia, Daniele Magnini, Rocco Trisolini, Filippo Lococo, Marco Chiappetta, Alessandra Cancellieri Abstract Objective: Malignant mesothelioma (MM) is usually diagnosed by histological examination of tissue samples; however, effusion cytology offers an opportunity to identify a strong possibility for mesothelioma diagnosis at an early stage. We conducted a retrospective analysis of…
Read More